BriaCell Therapeutics Corp.
BCTX
$3.06
$0.093.03%
NASDAQ
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.32% | 0.57% | 10.12% | 5.51% | -2.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.42% | 5.05% | 61.52% | 48.31% | -31.43% |
| Operating Income | -20.42% | -5.05% | -61.52% | -48.31% | 31.43% |
| Income Before Tax | -16.26% | -15.13% | -42.01% | -553.76% | -467.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.26% | -15.13% | -42.01% | -553.76% | -467.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -26.02% | 61.85% | 198.15% | 110.12% | 317.02% |
| Net Income | -16.94% | -14.79% | -41.28% | -566.40% | -457.09% |
| EBIT | -20.42% | -5.05% | -61.52% | -48.31% | 31.43% |
| EBITDA | -20.41% | -5.07% | -61.84% | -49.73% | 31.70% |
| EPS Basic | 93.98% | 88.94% | 86.68% | 9.46% | -201.98% |
| Normalized Basic EPS | 93.96% | 88.96% | 86.58% | 7.74% | -200.18% |
| EPS Diluted | 93.97% | 88.93% | 86.68% | 9.34% | -202.01% |
| Normalized Diluted EPS | 93.96% | 88.96% | 86.58% | 7.74% | -200.18% |
| Average Basic Shares Outstanding | 1,843.31% | 937.89% | 960.75% | 635.82% | 250.33% |
| Average Diluted Shares Outstanding | 1,843.31% | 937.89% | 960.75% | 635.82% | 250.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |